

References

- Aung, T. T., Yam, J. K. H., Lin, S., Salleh, S. M., Givskov, M., Liu, S., Lwin, N. C., Yang, L., & Beuerman, R. W. (2015). Biofilms of pathogenic nontuberculous mycobacteria targeted by new therapeutic approaches. *Antimicrobial Agents and Chemotherapy*, 60(1), 24–35. <https://doi.org/10.1128/aac.01509-15>
- Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence Data. (n.d.). <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>
- Bernut, A., Viljoen, A., Dupont, C., Sapriel, G., Blaise, M., Bouchier, C., Brosch, R., De Chastellier, C., Herrmann, J., & Kremer, L. (2015). Insights into the smooth-to-rough transitioning in *Mycobacterium boletii* unravel a functional Tyr residue conserved in all mycobacterial MmpL family members. *Molecular Microbiology*, 99(5), 866–883. <https://doi.org/10.1111/mmi.13283>
- Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*, 30(15), 2114–2120. <https://doi.org/10.1093/bioinformatics/btu170>
- Brambilla, C., Llorens-Fons, M., Julián, E., Noguera-Ortega, E., Tomàs-Martínez, C., Pérez-Trujillo, M., Byrd, T. F., Alcaide, F., & Luquin, M. (2016). Mycobacteria clumping increase their capacity to damage macrophages. *Frontiers in Microbiology*, 7. <https://doi.org/10.3389/fmicb.2016.01562>
- Bronson, R. A., Gupta, C., Manson, A. L., Nguyen, J. A., Bahadirli-Talbott, A., Parrish, N. M., Earl, A. M., & Cohen, K. A. (2021). Global phylogenomic analyses of *Mycobacterium abscessus* provide context for non cystic fibrosis infections and the evolution of antibiotic resistance. *Nature Communications*, 12(1). <https://doi.org/10.1038/s41467-021-25484-9>
- Brown-Elliott, B. A., Vasireddy, S., Vasireddy, R., Iakhiaeva, E., Howard, S. T., Nash, K., Parodi, N., Strong, A., Gee, M., Smith, T., & Wallace, R. J. (2015). Utility of Sequencing the erm (41) Gene in Isolates of *Mycobacterium abscessus* subsp. *abscessus* with Low and Intermediate

- Clarithromycin MICs. *Journal of Clinical Microbiology*, 53(4), 1211–1215.
<https://doi.org/10.1128/jcm.02950-14>
- Carneiro, M. D. S., De Souza Nunes, L., De David, S. M. M., & Barth, A. L. (2017). Lack of association between *rrl* and *erm*(41) mutations and clarithromycin resistance in *Mycobacterium abscessus* complex. *Memórias Do Instituto Oswaldo Cruz*, 112(11), 775–778.
<https://doi.org/10.1590/0074-02760170080>
- Cho, E. H., Huh, H. J., Song, D. J., Lee, S. H., Kim, C. K., Shin, S. Y., Ki, C., Jhun, B. W., Moon, S. M., Kwon, O. J., Koh, W., & Lee, N. Y. (2018). Drug susceptibility patterns of *Mycobacterium abscessus* and *Mycobacterium massiliense* isolated from respiratory specimens. *Diagnostic Microbiology and Infectious Disease*, 93(2), 107–111.
<https://doi.org/10.1016/j.diagmicrobio.2018.08.008>
- Chouhan, D., Retnakumar, R. J., Devi, T. B., Dharmaseelan, S., Alexander, S. M., Devadas, K., Chattopadhyay, S., Nair, G. B., & Pillai, M. R. (2023). Unusually high clarithromycin resistance in *Mycobacterium abscessus* subsp. *abscessus* isolated from human gastric epithelium. *Frontiers in Microbiology*, 14. <https://doi.org/10.3389/fmicb.2023.1193380>
- Clinical and Laboratory Standards Institute. (2018). Performance standards for susceptibility testing of mycobacteria, *Nocardia* spp., and other aerobic actinomycetes, 1st ed. CLSI document M62. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. (2023). Performance standards for susceptibility testing of mycobacteria, *Nocardia* spp., and other aerobic actinomycetes, 2nd ed. CLSI document M62. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. (2018). Susceptibility testing of mycobacteria, *Nocardia* spp., and other aerobic actinomycetes, 3rd ed, CLSI standard document M24. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clary, G., Sasindran, S. J., Nesbitt, N., Mason, L., Cole, S., Azad, A., McCoy, K., Schlesinger, L. S., & Hall-Stoodley, L. (2018). *Mycobacterium abscessus* Smooth and Rough Morphotypes Form

- Antimicrobial-Tolerant Biofilm Phenotypes but Are Killed by Acetic Acid. *Antimicrobial Agents and Chemotherapy*, 62(3). <https://doi.org/10.1128/aac.01782-17>
- Daniel-Wayman, S., Shallom, S., Azeem, N., Olivier, K. N., Zelazny, A. M., & Prevots, D. R. (2019). Amikacin exposure and susceptibility of macrolide-resistant *Mycobacterium abscessus*. *ERJ Open Research*, 5(2), 00154–02018. <https://doi.org/10.1183/23120541.00154-2018>
- Dedrick, R. M., Smith, B. E., Garlena, R. A., Russell, D. A., Aull, H. G., Mahalingam, V., Divens, A. M., Guerrero-Bustamante, C. A., Zack, K. M., Abad, L., Gauthier, C. H., Jacobs-Sera, D., & Hatfull, G. F. (2021). *Mycobacterium abscessus* Strain Morphotype Determines Phage Susceptibility, the Repertoire of Therapeutically Useful Phages, and Phage Resistance. *mBio*, 12(2). <https://doi.org/10.1128/mbio.03431-20>
- De Santana Lira, R. L., Nogueira, F. a. B., De Fátima Penna De Carvalho Campos, R., Ferreira, D. R. M., Roxo, P. L. B. T., De Azevedo, C. C. S., Gimenes, E. C. M., Bastos, R. L. C., Nascimento, C. E. C., Nunes, F. D. O., Marques, M. C. P., Campos, C. D. L., Martinez, C. G., Zagmignan, A., Silva, L. C. N., Ribeiro, R. M., De Azevedo Dos Santos, A. P. S., Carvalho, R. C., & De Sousa, E. M. (2025). *Mycobacterium abscessus* subsp. *massiliense*: Biofilm Formation, Host Immune Response, and Therapeutic Strategies. *Microorganisms*, 13(2), 447. <https://doi.org/10.3390/microorganisms13020447>
- Ding, J., Hameed, H. M. A., Long, L., Zhang, J., Fang, C., Tian, X., Zhang, H., Li, L., Li, C., Yang, R., Gao, Y., Wang, S., & Zhang, T. (2025). Correlation between *rrs* gene mutations and amikacin resistance in *Mycobacterium abscessus*: implications for fitness cost and clinical prevalence. *Journal of Antimicrobial Chemotherapy*. <https://doi.org/10.1093/jac/dkae468>
- Dinos, G. P. (2017). The macrolide antibiotic renaissance. *British Journal of Pharmacology*, 174(18), 2967–2983. <https://doi.org/10.1111/bph.13936>
- Dokic, A., Peterson, E., Arrieta-Ortiz, M. L., Pan, M., Di Maio, A., Baliga, N., & Bhatt, A. (2021). *Mycobacterium abscessus* biofilms produce an extracellular matrix and have a distinct mycolic acid profile. *The Cell Surface*, 7, 100051. <https://doi.org/10.1016/j.tcs.2021.100051>

- Fennelly, K. P., Ojano-Dirain, C., Yang, Q., Liu, L., Lu, L., Progulske-Fox, A., Wang, G. P., Antonelli, P., & Schultz, G. (2016). Biofilm Formation by *Mycobacterium abscessus* in a Lung Cavity. *American Journal of Respiratory and Critical Care Medicine*, 193(6), 692–693. <https://doi.org/10.1164/rccm.201508-1586im>
- Ferrell, K. C., Johansen, M. D., Triccas, J. A., & Counoupas, C. (2022). Virulence Mechanisms of *Mycobacterium abscessus*: Current Knowledge and Implications for Vaccine Design. *Frontiers in Microbiology*, 13. <https://doi.org/10.3389/fmicb.2022.842017>
- Gutiérrez, A. V., Viljoen, A., Ghigo, E., Herrmann, J., & Kremer, L. (2018). Glycopeptidolipids, a Double-Edged Sword of the *Mycobacterium abscessus* Complex. *Frontiers in Microbiology*, 9. <https://doi.org/10.3389/fmicb.2018.01145>
- Habboush, Y. & Guzman, N. (2023). *Antibiotic Resistance*. StatPearls - NCBI Bookshelf. <https://www.ncbi.nlm.nih.gov/books/NBK513277/>
- Hedin, W., Fröberg, G., Fredman, K., Chryssanthou, E., Selmer, I., Gillman, A., Orsini, L., Runold, M., Jönsson, B., Schön, T., & Forsman, L. D. (2023). A rough colony morphology of *Mycobacterium abscessus* associated with cavitary pulmonary disease and poor clinical outcome. *The Journal of Infectious Diseases*, 227(6), 820–827. <https://doi.org/10.1093/infdis/jiad007>
- Helou, G. E., Viola, G. M., Hachem, R., Han, X. Y., & Raad, I. I. (2013). Rapidly growing mycobacterial bloodstream infections. *The Lancet Infectious Diseases*, 13(2), 166–174. [https://doi.org/10.1016/s1473-3099\(12\)70316-x](https://doi.org/10.1016/s1473-3099(12)70316-x)
- Howard, S. T., Rhoades, E., Recht, J., Pang, X., Alsup, A., Kolter, R., Lyons, C. R., & Byrd, T. F. (2006). Spontaneous reversion of *Mycobacterium abscessus* from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. *Microbiology*, 152(6), 1581–1590. <https://doi.org/10.1099/mic.0.28625-0>
- Johansen, M. D., Herrmann, J., & Kremer, L. (2020). Non-tuberculous mycobacteria and the rise of *Mycobacterium abscessus*. *Nature Reviews Microbiology*, 18(7), 392–407. <https://doi.org/10.1038/s41579-020-0331-1>

- Kaiser, G. (2018). *BIOL 230 Lecture Guide - Flash Animation: Mode of action of aminoglycosides*. https://cwoer.ccbcmd.edu/science/microbiology/lecture/unit2/control/aglycomiscode_illus.html
- Kim, H., Kook, Y., Yun, Y., Park, C. G., Lee, N. Y., Shim, T. S., Kim, B., & Kook, Y. (2008). Proportions of *Mycobacterium massiliense* and *Mycobacterium bolletii* Strains among Korean *Mycobacterium chelonae*-*Mycobacterium abscessus* Group Isolates. *Journal of Clinical Microbiology*, 46(10), 3384–3390. <https://doi.org/10.1128/jcm.00319-08>
- Kim, H., Kim, B. J., Kook, Y., Yun, Y., Shin, J. H., Kim, B., & Kook, Y. (2010). *Mycobacterium massiliense* is differentiated from *Mycobacterium abscessus* and *Mycobacterium bolletii* by erythromycin ribosome methyltransferase gene (*erm*) and clarithromycin susceptibility patterns. *Microbiology and Immunology*, 54(6), 347–353. <https://doi.org/10.1111/j.1348-0421.2010.00221.x>
- Kumar, L., Bisen, M., Harjai, K., Chhibber, S., Azizov, S., Lalhlenmawia, H., & Kumar, D. (2023). Advances in nanotechnology for biofilm inhibition. *ACS Omega*, 8(24), 21391–21409. <https://doi.org/10.1021/acsomega.3c02239>
- Kurz, S. G., Zha, B. S., Herman, D. D., Holt, M. R., Daley, C. L., Ruminjo, J. K., & Thomson, C. C. (2020). Summary for clinicians: 2020 Clinical Practice Guideline Summary for the treatment of Nontuberculous mycobacterial Pulmonary Disease. *Annals of the American Thoracic Society*, 17(9), 1033–1039. <https://doi.org/10.1513/annalsats.202003-222cme>
- Larsen, M. H., Biermann, K., Tandberg, S., Hsu, T., & Jacobs, W. R. (2007). Genetic Manipulation of *Mycobacterium tuberculosis*. *Current Protocols in Microbiology*, 6(1). <https://doi.org/10.1002/9780471729259.mc10a02s6>
- Leclercq, L. D., Moigne, V. L., Daher, W., Cortes, M., Viljoen, B., Tasrini, Y., Trivelli, X., Lavanant, H., Schmitz-Afonso, I., Durand, N., Biet, F., Guérardel, Y., Kremer, L., & Herrmann, J. (2025). A glycosylated lipooctapeptide promotes uptake and growth of *Mycobacterium abscessus* in the host. *Nature Communications*, 16(1). <https://doi.org/10.1038/s41467-025-58455-5>

- Li, H., Handsaker, B., Wysocki, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., & Durbin, R. (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics*, 25(16), 2078–2079. <https://doi.org/10.1093/bioinformatics/btp352>
- Liu, W., Li, B., Chu, H., Zhang, Z., Luo, L., Ma, W., Yang, S., & Guo, Q. (2017). Rapid detection of mutations in *erm* (41) and *rhl* associated with clarithromycin resistance in *Mycobacterium abscessus* complex by denaturing gradient gel electrophoresis. *Journal of Microbiological Methods*, 143, 87–93. <https://doi.org/10.1016/j.mimet.2017.10.010>
- Lopeman, R. C., Harrison, J., Desai, M., & Cox, J. a. G. (2019). *Mycobacterium abscessus*: Environmental Bacterium Turned Clinical Nightmare. *Microorganisms*, 7(3), 90. <https://doi.org/10.3390/microorganisms7030090>
- Maxwell, A., Ghatge, V., Aranjani, J., & Lewis, S. (2021). Breaking the barriers for the delivery of amikacin: Challenges, strategies, and opportunities. *Life Sciences*, 284, 119883. <https://doi.org/10.1016/j.lfs.2021.119883>
- Munita, J. M., & Arias, C. A. (2016). Mechanisms of antibiotic resistance. *Microbiology Spectrum*, 4(2). <https://doi.org/10.1128/microbiolspec.vmbf-0016-2015>
- Nash, K. A., Brown-Elliott, B. A., & Wallace, R. J. (2009). A Novel Gene, *erm*(41), Confers Inducible Macrolide Resistance to Clinical Isolates of *Mycobacterium abscessus* but Is Absent from *Mycobacterium chelonae*. *Antimicrobial Agents and Chemotherapy*, 53(4), 1367–1376. <https://doi.org/10.1128/aac.01275-08>
- Nessar, R., Reyrat, J. M., Murray, A., & Gicquel, B. (2011). Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in *Mycobacterium abscessus*. *Journal of Antimicrobial Chemotherapy*, 66(8), 1719–1724. <https://doi.org/10.1093/jac/dkr209>
- Nguyen, T. Q., Heo, B. E., Jeon, S., Ash, A., Lee, H., Moon, C., & Jang, J. (2024). Exploring antibiotic resistance mechanisms in *Mycobacterium abscessus* for enhanced therapeutic approaches. *Frontiers in Microbiology*, 15. <https://doi.org/10.3389/fmicb.2024.1331508>

- Ong, L. T. (2024). Epidemiology of nontuberculous mycobacteria infection in Asia: A narrative review. *Indian Journal of Tuberculosis*. <https://doi.org/10.1016/j.ijtb.2024.08.006>
- Oschmann-Kadenbach, A. M., Schaudinn, C., Borst, L., Schwarz, C., Konrat, K., Arvand, M., & Lewin, A. (2024). Impact of *Mycobacteroides abscessus* colony morphology on biofilm formation and antimicrobial resistance. *International Journal of Medical Microbiology*, 314, 151603. <https://doi.org/10.1016/j.ijmm.2024.151603>
- Park, I. K., Hsu, A. P., Tettelin, H., Shallom, S. J., Drake, S. K., Ding, L., Wu, U., Adamo, N., Prevots, D. R., Olivier, K. N., Holland, S. M., Sampaio, E. P., & Zelazny, A. M. (2015). Clonal Diversification and Changes in Lipid Traits and Colony Morphology in *Mycobacterium abscessus* Clinical Isolates. *Journal of Clinical Microbiology*, 53(11), 3438–3447. <https://doi.org/10.1128/jcm.02015-15>
- Patel, P. H., & Hashmi, M. F. (2023, May 16). *Macrolides*. StatPearls - NCBI Bookshelf. <https://www.ncbi.nlm.nih.gov/books/NBK551495/>
- Patel, R. R., Arun, P. P., Singh, S. K., & Singh, M. (2024). Mycobacterial biofilms: Understanding the genetic factors playing significant role in pathogenesis, resistance and diagnosis. *Life Sciences*, 351, 122778. <https://doi.org/10.1016/j.lfs.2024.122778>
- Peterson, E., & Kaur, P. (2018). Antibiotic resistance mechanisms in bacteria: relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens. *Frontiers in Microbiology*, 9. <https://doi.org/10.3389/fmicb.2018.02928>
- PubChem. (n.d.). *Clarithromycin*. PubChem. <https://pubchem.ncbi.nlm.nih.gov/compound/Clarithromycin>
- Qvist, T., Eickhardt, S., Kragh, K. N., Andersen, C. B., Iversen, M., Høiby, N., & Bjarnsholt, T. (2015). Chronic pulmonary disease with *Mycobacterium abscessus* complex is a biofilm infection. *European Respiratory Journal*, 46(6), 1823–1826. <https://doi.org/10.1183/13993003.01102-2015>

- Raaijmakers, J., Schildkraut, J. A., Hoefsloot, W., & Van Ingen, J. (2021). The role of amikacin in the treatment of nontuberculous mycobacterial disease. *Expert Opinion on Pharmacotherapy*, 22(15), 1961–1974. <https://doi.org/10.1080/14656566.2021.1953472>
- Ramirez, M., & Tolmasky, M. (2017). Amikacin: uses, resistance, and prospects for inhibition. *Molecules*, 22(12), 2267. <https://doi.org/10.3390/molecules22122267>
- Rather, M. A., Gupta, K., & Mandal, M. (2021). Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. *Brazilian Journal of Microbiology*, 52(4), 1701–1718. <https://doi.org/10.1007/s42770-021-00624-x>
- Realegeno, S., Mirasol, R., Garner, O. B., & Yang, S. (2021). Clinical Whole Genome Sequencing for Clarithromycin and Amikacin Resistance Prediction and Subspecies Identification of *Mycobacterium abscessus*. *Journal of Molecular Diagnostics*, 23(11), 1460–1467. <https://doi.org/10.1016/j.jmoldx.2021.07.023>
- Reygaert, W. C. (2018). An overview of the antimicrobial resistance mechanisms of bacteria. *AIMS Microbiology*, 4(3), 482–501. <https://doi.org/10.3934/microbiol.2018.3.482>
- Richard, M., Gutiérrez, A. V., & Kremer, L. (2019). Dissecting erm (41)-Mediated Macrolide-Inducible Resistance in *Mycobacterium abscessus*. *Antimicrobial Agents and Chemotherapy*, 64(2). <https://doi.org/10.1128/aac.01879-19>
- Roux, A., Viljoen, A., Bah, A., Simeone, R., Bernut, A., Laencina, L., Deramaudt, T., Rottman, M., Gaillard, J., Majlessi, L., Brosch, R., Girard-Misguich, F., Vergne, I., De Chastellier, C., Kremer, L., & Herrmann, J. (2016). The distinct fate of smooth and rough *Mycobacterium abscessus* variants inside macrophages. *Open Biology*, 6(11), 160185. <https://doi.org/10.1098/rsob.160185>
- Ruedas-López, A., Tato, M., Broncano-Lavado, A., Esteban, J., Ruiz-Serrano, M. J., Sánchez-Cueto, M., Toro, C., Domingo, D., Cacho, J., Barrado, L., & López-Roa, P. (2023). Subspecies Distribution and Antimicrobial Susceptibility Testing of *Mycobacterium abscessus* Clinical Isolates in

- Madrid, Spain: a Retrospective Multicenter Study. *Microbiology Spectrum*, 11(3).
<https://doi.org/10.1128/spectrum.05041-22>
- Rüger, K., Hampel, A., Billig, S., Rücker, N., Suerbaum, S., & Bange, F. (2013). Characterization of Rough and Smooth Morphotypes of *Mycobacterium abscessus* Isolates from Clinical Specimens. *Journal of Clinical Microbiology*, 52(1), 244–250. <https://doi.org/10.1128/jcm.01249-13>
- Saxena, S., Spaink, H. P., & Forn-Cuní, G. (2021). Drug resistance in nontuberculous mycobacteria: mechanisms and models. *Biology*, 10(2), 96. <https://doi.org/10.3390/biology10020096>
- Sizar, O., Rahman, S., & Sundareshan, V. (2023, July 17). *Amikacin*. StatPearls - NCBI Bookshelf. <https://www.ncbi.nlm.nih.gov/books/NBK430908/>
- Sievers, F., & Higgins, D. G. (2013). Clustal Omega, accurate alignment of very large numbers of sequences. *Methods in Molecular Biology*, 105–116. https://doi.org/10.1007/978-1-62703-646-7_6
- Stepanović, S., Vuković, D., Hola, V., Di Bonaventura, G., Djukić, S., Ćirković, I., & Ruzicka, F. (2007). Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. *Apmis*, 115(8), 891–899. https://doi.org/10.1111/j.1600-0463.2007.apm_630.x
- Sukmongkolchai, S., Petsong, S., Oudomying, N., Prommi, A., Payungporn, S., Usawakidwiree, W., Wongjarit, K., Suwanpimolkul, G., Faksri, K., Suankratay, C., & Rotcheewaphan, S. (2023). Clinical characteristics and drug susceptibility profiles of *Mycobacterium abscessus* complex infection at a medical school in Thailand. *Annals of Clinical Microbiology and Antimicrobials*, 22(1). <https://doi.org/10.1186/s12941-023-00637-4>
- To, K., Cao, R., Yegiazaryan, A., Owens, J., & Venketaraman, V. (2020). General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: *Mycobacterium avium* and *Mycobacterium abscessus*. *Journal of Clinical Medicine*, 9(8), 2541. <https://doi.org/10.3390/jcm9082541>

- Victoria, L., Gupta, A., Gómez, J. L., & Robledo, J. (2021). Mycobacterium abscessus complex: A Review of Recent Developments in an Emerging Pathogen. *Frontiers in Cellular and Infection Microbiology*, 11. <https://doi.org/10.3389/fcimb.2021.659997>
- Wang, L., Fan, D., Chen, W., & Terentjev, E. M. (2015). Bacterial growth, detachment and cell size control on polyethylene terephthalate surfaces. *Scientific Reports*, 5(1). <https://doi.org/10.1038/srep15159>
- Wang, X., Su, B., Chen, P., Kuang, H., Guan, P., Zhang, C., Pan, L., Zhu, J., & Tan, Y. (2025). Subspecies distribution and drug-resistance characteristics of Mycobacterium abscessus complex clinical isolates in South China. *Microbiology Spectrum*. <https://doi.org/10.1128/spectrum.04103-23>
- Wu, M., Li, B., Guo, Q., Xu, L., Zou, Y., Zhang, Y., Zhan, M., Xu, B., Ye, M., Yu, F., Zhang, Z., & Chu, H. (2019). Detection and molecular characterisation of amikacin-resistant Mycobacterium abscessus isolated from patients with pulmonary disease. *Journal of Global Antimicrobial Resistance*, 19, 188–191. <https://doi.org/10.1016/j.jgar.2019.05.016>
- Yang, T., Beach, K. E., Zhu, C., Gan, M., Wang, W., Zhou, H., Peng, L., Wang, S., Cai, L., Li, W., Davis, J. B., Cicchetti, N., Slechta, E. S., Barker, A., Shakir, S. M., Carey, A. F., & Liu, Q. (2024). Genomic analysis of global Mycobacterium abscessus isolates reveals ongoing evolution of drug-resistance-associated genes. *The Journal of Infectious Diseases*. <https://doi.org/10.1093/infdis/jiae580>
- Zhao, A., Sun, J., & Liu, Y. (2023). Understanding bacterial biofilms: From definition to treatment strategies. *Frontiers in Cellular and Infection Microbiology*, 13. <https://doi.org/10.3389/fcimb.2023.1137947>